Immunovant, Inc. (IMVT) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2026, Immunovant reported revenue of $0. Net income was -$505.6M, or -$2.77 per diluted share. Operating activities generated -$407.3M of cash, leaving -$407.3M of free cash flow. At fiscal year end, Immunovant held $957.0M in total assets against $104.4M in total liabilities, including $902.1M of cash and equivalents.
Open the full interactive Immunovant financials → Quarterly statements, key ratios, valuation history and price charts.
Immunovant Key Stats
| Share Price | $28.71 |
|---|---|
| Market Cap | $5.90B |
| 52-Week Range | $17.35 – $44.96 |
| Shares Outstanding | 205.5 million (basic, 2027 Q1) |
Immunovant Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$107.8M | -$156.8M | -$211.0M | -$258.8M | -$412.9M | -$505.4M |
| Income Tax | -$358,000 | -$84,000 | $9,000 | $567,000 | $891,000 | $215,000 |
| Net Income | -$107.4M | -$156.7M | -$211.0M | -$259.3M | -$413.8M | -$505.6M |
| Diluted EPS | -$1.22 | -$1.43 | -$1.71 | -$1.88 | -$2.73 | -$2.77 |
Immunovant Quarterly Results
| 2026 Q2 | 2026 Q3 | 2026 Q4 | 2027 Q1 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$126.5M | -$110.6M | -$147.9M | -$153.2M |
| Diluted EPS | -$0.73 | -$0.61 | -$0.81 | -$0.75 |
Immunovant Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $400.1M | $493.8M | $376.5M | $635.4M | $714.0M | $902.1M |
| Current Assets | $409.0M | $512.9M | $404.3M | $665.8M | $767.7M | $948.8M |
| Total Assets | $412.5M | $515.6M | $405.8M | $666.4M | $776.2M | $957.0M |
| Current Liabilities | $18.8M | $44.5M | $43.3M | $48.6M | $68.8M | $104.4M |
| Total Liabilities | $21.0M | $45.7M | $43.3M | $48.6M | $68.8M | $104.4M |
| Shareholders' Equity | $391.5M | $469.8M | $362.5M | $617.8M | $707.4M | $852.6M |
Immunovant Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$83.3M | -$106.1M | -$188.2M | -$214.2M | -$375.9M | -$407.3M |
| Cash From Investing | -$210,000 | -$254,000 | -$197,000 | -$360,000 | -$759,000 | -$8,000 |
| Cash From Financing | $383.1M | $200.1M | $70.9M | $472.4M | $454.5M | $595.8M |
| Free Cash Flow | -$83.5M | -$106.4M | -$188.4M | -$214.6M | -$376.6M | -$407.3M |
Figures from Immunovant's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Immunovant financials page for every line item.
Immunovant Company Profile
| Ticker | IMVT |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Durham, North Carolina |
| Incorporated in | Delaware |
| Fiscal Year End | March 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001764013 |
Frequently Asked Questions
What was Immunovant's revenue in fiscal 2026?
Immunovant (IMVT) reported revenue of $0 for fiscal 2026.
What is Immunovant's annual revenue history?
Immunovant's annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0; 2026: $0.
What was Immunovant's net income in fiscal 2026?
Immunovant reported net income of -$505.6M for fiscal 2026.
What was Immunovant's earnings per share (EPS) in fiscal 2026?
Immunovant's diluted EPS was -$2.77 for fiscal 2026 (adjusted for any later stock splits).
How much free cash flow did Immunovant generate in fiscal 2026?
Immunovant generated -$407.3M of free cash flow in fiscal 2026.
What was Immunovant's revenue last quarter?
In its most recent reported quarter (2027 Q1), Immunovant reported revenue of $0.
How many shares of Immunovant are outstanding?
Immunovant reported a weighted average of 205.5 million basic shares outstanding in 2027 Q1.
What is Immunovant's market cap?
Based on its latest closing price, Immunovant (IMVT) has a market capitalization of about $5.90B.
When does Immunovant's fiscal year end?
Immunovant's fiscal year end, as registered with the SEC, is March 31.
Where is Immunovant headquartered?
Immunovant lists its business address in Durham, North Carolina in its SEC filings.
Immunovant Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →